Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study.
Birkeland KI, Bodegard J, Eriksson JW, Norhammar A, Haller H, Linssen GCM, Banerjee A, Thuresson M, Okami S, Garal-Pantaler E, Overbeek J, Mamza JB, Zhang R, Yajima T, Komuro I, Kadowaki T. Birkeland KI, et al. Among authors: mamza jb. Diabetes Obes Metab. 2020 Sep;22(9):1607-1618. doi: 10.1111/dom.14074. Epub 2020 Jun 3. Diabetes Obes Metab. 2020. PMID: 32363737 Free PMC article.
Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.
Birkeland KI, Bodegard J, Banerjee A, Kim DJ, Norhammar A, Eriksson JW, Thuresson M, Okami S, Ha KH, Kossack N, Mamza JB, Zhang R, Yajima T, Komuro I, Kadowaki T. Birkeland KI, et al. Among authors: mamza jb. Diabetes Obes Metab. 2021 Jan;23(1):75-85. doi: 10.1111/dom.14189. Epub 2020 Sep 28. Diabetes Obes Metab. 2021. PMID: 32893440 Free PMC article.
Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
Idris I, Zhang R, Mamza JB, Ford M, Morris T, Banerjee A, Khunti K. Idris I, et al. Among authors: mamza jb. Diabetes Obes Metab. 2021 Oct;23(10):2207-2214. doi: 10.1111/dom.14437. Epub 2021 Aug 2. Diabetes Obes Metab. 2021. PMID: 33973690 Free PMC article.
Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.
Idris I, Zhang R, Mamza JB, Ford M, Morris T, Banerjee A, Khunti K. Idris I, et al. Among authors: mamza jb. Diabetes Obes Metab. 2022 Nov;24(11):2138-2147. doi: 10.1111/dom.14799. Epub 2022 Jul 6. Diabetes Obes Metab. 2022. PMID: 35676798 Free PMC article.
A retrospective cohort study predicting and validating impact of the COVID-19 pandemic in individuals with chronic kidney disease.
Dashtban A, Mizani MA, Denaxas S, Nitsch D, Quint J, Corbett R, Mamza JB, Morris T, Mamas M, Lawlor DA, Khunti K; CVD-COVID-UK Consortium; Sudlow C, Hemingway H, Banerjee A. Dashtban A, et al. Among authors: mamza jb. Kidney Int. 2022 Sep;102(3):652-660. doi: 10.1016/j.kint.2022.05.015. Epub 2022 Jun 17. Kidney Int. 2022. PMID: 35724769 Free PMC article.
Identifying subtypes of chronic kidney disease with machine learning: development, internal validation and prognostic validation using linked electronic health records in 350,067 individuals.
Dashtban A, Mizani MA, Pasea L, Denaxas S, Corbett R, Mamza JB, Gao H, Morris T, Hemingway H, Banerjee A. Dashtban A, et al. Among authors: mamza jb. EBioMedicine. 2023 Mar;89:104489. doi: 10.1016/j.ebiom.2023.104489. Epub 2023 Feb 27. EBioMedicine. 2023. PMID: 36857859 Free PMC article.
33 results